Drugs / SCT510A
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04564937 | Nov 2020 → Apr 2022 | wet macular degeneration | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05480293 | Feb 2023 → Jul 2025 | wet macular degeneration | Sinocelltech Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCT510A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05480293 ↗ |
| Action | Inhibit | “anti-VEGF” NCT04564937 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized anti-VEGF monoclonal antibody（SCT510A）” NCT04564937 ↗ |
| Route | Intravitreal | “Vitreous injection” NCT04564937 ↗ |